#Liquid Biopsy Market Share

[healthcaremarketanalysis]

Liquid Biopsy market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a latest report published by MarketsandMarkets™.

With the increasing incidence & prevalence of cancer worldwide, there's a growing need for effective methods of early detection, therapy selection, monitoring treatment response, and detecting disease recurrence. Liquid biopsies provide a promising solution by enabling clinicians to detect and analyze cancer-related biomarkers more easily and frequently than traditional tissue biopsies. The burgeoning adoption and recognition of liquid biopsy's advantages over traditional biopsy methods are also propelling a robust evolution in liquid biopsy products and services. However, lack of desired sensitivity and specificity in certain liquid biopsy products is likely to restrain the growth of the market.

[renubresearch]

Liquid Biopsy Market is expected to reach US$ 10.08 Billion by 2030

Renub Research has released a report titled “Global Liquid Biopsy Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2030,” which includes market percentage records and a thorough enterprise analysis. This report looks at the global liquid biopsy market’s competition, geographic distribution, and growth potential. Expert Insights: Ask Analyst or Download Full Report…

[marketdevelopment]

Liquid Biopsy Market Latest Innovations, Drivers and Industry Status 2023 to 2030

The Global Liquid Biopsy Market size is expected to grow from USD 1.59 billion in 2022 to USD 7.02 billion by 2030, at a CAGR of 20.4% during the forecast period (2023-2030).

A liquid biopsy is a minimally invasive diagnostic procedure that involves analyzing various biomarkers (such as circulating tumor cells, cell-free DNA, exosomes, and other nucleic acids) found in bodily fluids like blood, urine, or saliva. It's primarily used for the detection and monitoring of diseases, particularly cancer.

Advances in technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and digital PCR have greatly enhanced the sensitivity and specificity of liquid biopsy tests, enabling more accurate detection and monitoring of diseases.

Liquid biopsies have gained particular attention in the field of oncology for early cancer detection, monitoring treatment response, and detecting resistance mutations. They offer a non-invasive alternative to tissue biopsies and can provide real-time information on tumor dynamics.

While oncology remains the primary focus of liquid biopsy applications, researchers and companies have been exploring its potential in other areas such as prenatal testing, infectious disease diagnostics, transplant monitoring, and autoimmune disease detection.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @

https://introspectivemarketresearch.com/request/16300

Updated Version 2024 is available our Sample Report May Includes the:

Scope For 2024

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by Worldwide Market Reports

Leading players involved in the Liquid Biopsy Market include:

Agilent Technologies (United States), Bio-Rad Laboratories, Inc. (United States), Beckman Coulter(United States), Illumina (United States), PerkinElmer (United States), Becton, Dickinson and Company (BD) (United States), Johnson & Johnson (United States), Abbott Laboratories (United States), Cancer Genetics, Inc. (United States), Myriad Genetics, Inc. (United States) 

Moreover, the report includes significant chapters such as Patent Analysis, Regulatory Framework, Technology Roadmap, BCG Matrix, Heat Map Analysis, Price Trend Analysis, and Investment Analysis which help to understand the market direction and movement in the current and upcoming years. 

If You Have Any Query Liquid Biopsy Market Report, Visit:

https://introspectivemarketresearch.com/inquiry/16300

Segmentation of Liquid Biopsy Market:

By Cancer Type

Lung

Breast

Liver

By Circulating Biomarker

Circulating Tumor DNA

Circulating Tumor Cells

By End-User

Hospitals

Laboratories

Government Research Centre

By Regions: -

North America (US, Canada, Mexico)

Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)

Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)

Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)

Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)

South America (Brazil, Argentina, Rest of SA)

Key Reasons To Invest In Liquid Biopsy Market Report:

To provide a complete structure and a basic overview of the Liquid Biopsy market.

To provide insights into important Liquid Biopsy aspects such as growth trajectory, CAGR value, market share, and revenue analysis.

Assess growth opportunities, threats, market drivers, and associated risks.

To understand the Liquid Biopsy market competition by analysing the top business people along with market profiles, import/export details, revenue, profit, and market shares.

Indicate pricing structure, import/export details, supply chain analysis, SWOT analysis to facilitate key decision-making process.

Analysing emerging Liquid Biopsy market segments and sub-segments to drive ultimate growth, investment analysis, and future growth opportunities.

Understand sources of knowledge, intended research methodology, and important conclusions.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Acquire This Reports: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=16300

About us:

Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assisting our clients to grow and have a successful impact on the market. Our team at IMR is ready to assist our clients to flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, that specializes in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyse extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.

Contact us:

Introspective Market Research

3001 S King Drive,

Chicago, Illinois

60616 USA

Ph no: +1-773-382-1047

Email: sales@introspectivemarketresearch.com

[123567-9qaaq9]

Liquid Biopsy Market Research Is Expected to Increase Growth Steadily By (predicted year) | Bis Research

The global liquid biopsy market was estimated to be at $2,508.2 million in 2021, which is expected to grow with a CAGR of 19.83% and reach $19,066.0 million by 2032. The growth in the global liquid biopsy market is expected to be driven by increasing adoption of NGS in various research fields, advancement in NGS, and increase in the adoption of personalized medicine

Market Overview:

The liquid biopsy market has experienced significant growth in recent years, driven by increasing prevalence of cancer, advancements in genomic research, and the need for personalized medicine. According to recent market reports, the global liquid biopsy market is projected to witness a compound annual growth rate (CAGR) of X% during the forecast period.

Traditional biopsy methods often involve invasive procedures to extract tissue samples for analysis. Liquid biopsy, on the other hand, offers a minimally invasive alternative by analyzing biomarkers present in body fluids such as blood, urine, or saliva. The primary focus of liquid biopsy is on detecting and monitoring genetic alterations, particularly in the context of cancer.

Key Market Drivers:

Rising Incidence of Cancer: With cancer becoming a leading cause of mortality worldwide, the demand for accurate and non-invasive diagnostic methods has surged. Liquid biopsy provides a valuable tool for early cancer detection, which can significantly enhance treatment outcomes.

Advancements in Genomic Research: The rapid progress in genomic research has paved the way for a deeper understanding of the genetic basis of diseases. Liquid biopsy, by analyzing circulating tumor DNA (ctDNA) and other biomarkers, facilitates the identification of specific genetic mutations associated with cancer.

Personalized Medicine: The shift towards personalized medicine has underscored the importance of precise diagnostics. Liquid biopsy allows for real-time monitoring of genetic changes, enabling clinicians to tailor treatment plans based on the evolving genetic profile of the tumor.

Market Challenges:

While the liquid biopsy market presents immense potential, it is not without challenges:

Standardization and Validation: Establishing standardized procedures and validating the accuracy and reliability of liquid biopsy tests remain crucial for widespread adoption.

Costs and Reimbursement: The initial costs of liquid biopsy tests may pose a barrier to accessibility for some patients. Addressing reimbursement issues and reducing costs will be essential for broader market penetration.

Regulatory Hurdles: Regulatory approval processes for liquid biopsy tests need to be streamlined to ensure timely market entry while maintaining rigorous quality and safety standards.

Get your hands on this Sample Report to stay up-to-date on the latest developments in this Market. Download now @ Liquid Biopsy Market 

Market Segmentation 

By Offering

 By Technology

By Workflow 

The liquid biopsy market can be segmented based on:

Cancer Type: Different cancers exhibit distinct genetic signatures. Liquid biopsy tests are often tailored for specific cancer types, such as lung cancer, breast cancer, colorectal cancer, and others.

Biomarker Type: Liquid biopsy can analyze various biomarkers, including ctDNA, circulating tumor cells (CTCs), exosomes, and microRNAs, each providing unique insights into disease progression.

End User: The market caters to hospitals, diagnostic laboratories, academic research institutions, and pharmaceutical companies.

Future Outlook:

The liquid biopsy market is poised for continued growth, driven by ongoing research and development, technological advancements, and increasing awareness among healthcare professionals and patients. As the technology evolves, it is expected to play a pivotal role in early cancer detection, treatment monitoring, and guiding therapeutic decisions.

Conclusion:

In conclusion, the liquid biopsy market is a dynamic and rapidly evolving sector within the broader field of healthcare diagnostics. As the global healthcare landscape continues to shift towards precision medicine, liquid biopsy stands at the forefront, offering a promising avenue for non-invasive, personalized, and real-time monitoring of diseases, particularly cancer. Keeping a close eye on regulatory developments, technological innovations, and market trends will be crucial for stakeholders seeking to capitalize on the transformative potential of liquid biopsy in the years to come.

[kirancmi]

Liquid Biopsy Is Estimated To Witness High Growth Owing To Ease Of Use And Non-Invasive Process

Liquid biopsy is a non-invasive alternative to surgical biopsy that analyzes blood samples to diagnose cancer and other diseases. It allows doctors to detect cancer recurrence earlier and monitor treatment effectiveness with simple blood draws, instead of painful tissue biopsies. The global liquid biopsy market includes products and services required for liquid biopsy testing including reagents and kits, instruments, and services. The technology is useful for monitoring disease progression and identifying therapeutic options for advance stage cancer patients.

The global liquid biopsy Market is estimated to be valued at US$ 5.25 Bn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: The global liquid biopsy market is witnessing significant growth owing to the ease of use and non-invasive process of liquid biopsy as compared to traditional tissue biopsy. As liquid biopsy relies on blood draws it eliminates risks associated with surgical biopsies like infection, scarring, and pain. This has increased adoption amongst patients and healthcare providers for early cancer detection and monitoring. Further, ongoing research and development of liquid biopsy technologies especially for detection of multiple cancer types from a single blood draw is also driving market growth. Various players are focused on development of assays and tests with high sensitivity and specificity to detect even minimum traces of circulating tumor DNA (ctDNA) in bloodstream. However, complex regulatory processes and reimbursement challenges remains a restraining factor in market growth. Liquid biopsy is yet to gain approval for screening of early cancer detection from regulatory bodies. Lack of reimbursement policies also hinders widespread clinical adoption. Nevertheless, ongoing approvals and establishment of reimbursement codes is expected to address these challenges in coming years propelling liquid biopsy market growth. SWOT Analysis Strength: The liquid biopsy market offers non-invasive and cost-effective alternatives to tissue biopsy. It can detect multiple types of cancer from a simple blood draw. This reduces risks associated with invasive surgical biopsy procedures. Liquid biopsy also enables longitudinal monitoring of cancer during and after treatment from blood draws. Weakness: Liquid biopsy tests still need improvements to achieve accuracy levels comparable to tissue biopsy. False positive and false negative results are possible challenges. Limited clinical evidence also means liquid biopsy may not be reimbursed or accepted by regulatory agencies for certain clinical uses. Opportunity: The rising cancer burden worldwide generates vast opportunities for liquid biopsy adoption. Early cancer screening and detection is a key growth driver. Liquid biopsy provides hope for precision and personalized cancer monitoring and management. Growing investments in cancer research support liquid biopsy commercialization. Threats: Intellectual property disputes between companies could impact liquid biopsy innovations. Slow regulatory approvals may limit timely commercialization. Established diagnostic procedures pose competition. Reimbursement policies influence market acceptance. Key Takeaways The global liquid biopsy market size is expected to witness high growth. It is estimated to reach a value of US$ 5.25 billion by 2024, registering a CAGR of 6.7% during the forecast period of 2023 to 2030.

North America currently dominates the market due to rising healthcare investments and growing focus on precision medicine in oncology. Asia Pacific is expected to offer lucrative opportunities owing to increasing cancer incidence, growing healthcare expenditure, and expanding biotechnology industry in countries like China and India. Key players

 operating in the liquid biopsy market are BASF SE, Spectrum Chemical Manufacturing Corp., Kudos Chemie Limited, AVT Natural Products, Tianjin Zhong€TMan, Pharmaceutical Company Ltd., Shandong Xinhua Pharma, Aarti Industries Limited, Bakul Group, Taj Pharmaceuticals Limited., and Jilin Shulan Synthetic Pharmaceutical Co. Ltd. The market is fairly consolidated with large corporations having wide geographical presence and strong foothold. However, small players contribute significantly through novel technologies and regional expertise. Strategic collaborations between companies allow leveraging complementary strengths to commercialize new liquid biopsy applications. Overall, the rapidly evolving oncology diagnostics domain presents immense growth potential for liquid biopsy.

Get more insights on this topic: https://www.newsstatix.com/liquid-biopsy-market-industry-insights-trends-liquid-biopsy-market/

Explore more information on this topic, Please visit: https://allmeaninginhindi.com/navigating-the-evolving-landscape-of-enterprise-artificial-intelligence-solutions/

[desaletushki]

Liquid Biopsy Market Size, Share & Trends Analysis Report, 2030

Liquid Biopsy Market Growth & Trends

The global liquid biopsy market size is expected to reach USD 22.86 billion by 2030, expanding at a CAGR of 12.46% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancer and the growing geriatric population are major drivers expected to fuel market growth. Furthermore, the use of technologically advanced devices for early detection of diseases is one of the key factors driving the market. In addition, the increasing preference for noninvasive treatment procedures will offer lucrative opportunities in the forecast period.

In recent years, cases of cancer have been rising tremendously and the trend is projected to remain the same in the foreseeable future. A significant shift in lifestyle has exposed the global population to this disorder and has resulted in oncogenic factors. For instance, as per the American Cancer Society, in 2022, the number of new cancer cases is expected to reach 1.9 million, leading to 609,360 deaths. Companies are focusing on expanding their business operations in the clinical liquid biopsy space.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market

For instance, in December 2021, Helio Health and Fulgent Genetics announced the launch of the former’s HelioLiver, a new liquid biopsy test for early liver cancer detection. This liquid biopsy test combines serum protein markers and cell-free DNA methylation patterns. Additionally, new research studies are aiding the development of novel liquid biopsy techniques. For instance, in July 2022, the University of Central Florida announced the development of a novel liquid biopsy technique that facilitates early detection using biomarker identification for lung and breast cancer, making the monitoring of conditions easier.

The enhanced interest of players in liquid biopsy and the increasing rate of approval of new products are further accelerating market growth. Moreover, in the past several years, studies have shown a positive outcome of liquid biopsy platforms. Governments and various regulatory bodies have also shown interest in the area by promoting multiple breakthrough devices for the rapid development of this technology. With the high adoption of the technology by various companies, along with the support of government funding and initiatives, the market is expected to grow in the coming years.

Liquid Biopsy Market Report Highlights

The ctDNA segment is projected to hold the largest share in the market owing to its wide use as a biomarker in the detection of cancer using liquid biopsy

The multi-gene-parallel analysis (NGS) technology segment is expected to grow lucratively due to increasing research and development, increasing cancer cases, advancements in technology, and strategic activities by leading companies

North America dominated the global market in 2022, owing to the increasing demand for new technologies, a large pool of key players, the presence of several clinical laboratories, and advanced healthcare infrastructure in the region

Asia Pacific is expected to grow considerably in the future, owing to the rising prevalence of target conditions in the region and the presence of key players

Liquid Biopsy Market Segmentation

Grand View Research has segmented the global liquid biopsy market based on sample type, biomarker, technology, application, end-use, clinical application, product, and region:

Liquid Biopsy Sample Type Outlook (Revenue, USD Billion, 2018 - 2030)

Blood Sample

Others

Liquid Biopsy Biomarker Outlook (Revenue, USD Billion, 2018 - 2030)

Circulating Tumor Cells (CTCs)

Circulating Tumor DNA (ctDNA)

Extracellular Vesicles (EVs)

Others

Liquid Biopsy Technology Outlook (Revenue, USD Billion, 2018 - 2030)

Multi-gene-parallel Analysis (NGS)

Single Gene Analysis (PCR Microarrays)

Liquid Biopsy Application Outlook (Revenue, USD Billion, 2018 - 2030)

Cancer

Lung Cancer

Prostate Cancer

Breast Cancer

Colorectal Cancer

Leukemia 

Gastrointestinal Cancer

Others

Reproductive Health

Others

Liquid Biopsy End-use Outlook (Revenue, USD Billion, 2018 - 2030)

Hospitals and Laboratories

Specialty Clinics

Academic and Research Centers

Others

Liquid BiopsyClinical Application Outlook (Revenue, USD Billion, 2018 - 2030)

Therapy Selection

Treatment Monitoring

Early Cancer Screening

Recurrence Monitoring

Others

Liquid Biopsy Product Outlook (Revenue, USD Billion, 2018 - 2030)

Instruments

Consumables Kits and Reagents

Software and Services

Regional Insights

The North America market for liquid biopsy led with a revenue share of 50.93% in 2022, owing to high cancer prevalence, rapid technological advancements, and growing government initiatives. Moreover, rapid advancements in technology and intense competition between biotechnology companies aided by recent FDA approvals for liquid biopsy tests are among the factors expected to boost regional market growth over the forecast period. For instance, in November 2020, the FDA approved the liquid biopsy NGS-based FoundationOne Liquid CDx test for multiple cancers and biomarkers.

On the other hand, Asia Pacific is projected to exhibit the fastest CAGR over the forecast period. Some of the factors contributing to the market growth are improving healthcare infrastructure, a growing population, and a rising number of companies entering the market. Asia Pacific has a large population, along with a high prevalence of cancer. According to Global Cancer Statistics 2020, an estimated one-half of all cases and around 58.3% of deaths occurred in Asia in 2020.

Thus, usage of screening tests for cancer has increased in the past few years, owing to growing government initiatives such as free screening for cervical, breast, & lung cancer, and increased collaborations between governments, research institutes, & companies for the distribution and supply of these tests.

List of Key Players of Liquid Biopsy Market

ANGLE plc

Oncimmune

Guardant Health, Inc.

Myriad Genetics, Inc.

Biocept, Inc.

Lucence Health Inc.

Freenome Holdings, Inc.

Hoffmann-La Roche Ltd.

QIAGEN

Illumina, Inc.

Thermo Fisher Scientific, Inc.

Epigenomics AG

Authoritative Research: https://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market

[businessintelligenceinsightsblog]

As per Business Intelligence Insights (BII) study, the global Liquid Biopsy Market attained revenue growth of USD 2394.10 million in 2021 and it is projected to reach around USD 6365.03 million by 2028, growing at a 17.70 % CAGR.

[aarunresearcher]

United States liquid biopsy market size reached USD 563.6 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,775.8 Million by 2033, exhibiting a growth rate (CAGR) of 13.6% during 2025-2033. The rising need for personalized treatments among individuals across the country is propelling the adoption of this method to analyze the genetic mutations in an efficient manner, which is primarily driving the market growth.

[healthcaremarketanalysis]

Liquid Biopsy Market worth $11.3 billion by 2029

Liquid Biopsy Market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a new report by MarketsandMarkets™.

In recent years, there has been substantial growth in the liquid biopsy market. The increasing burden of cancer cases globally has highlighted the urgent requirement for more effective and less invasive diagnostic tools. In this context, liquid biopsy emerges as a highly valuable solution. Unlike traditional tissue biopsies, which often involve invasive procedures and can be associated with discomfort and risks for patients, liquid biopsy offers a non-invasive alternative for detecting and monitoring cancer. Furthermore, these tests can also be used in non-invasive prenatal testing and transplantation medicine. Thus, these advantages are driving the rapid evolution and uptake of liquid biopsy products and services in disease diagnosis, treatment, and monitoring.

Liquid Biopsy Market Trends

Download an Illustrative overview:

Browse in-depth TOC on "Liquid Biopsy Market"

406 - Tables

56 - Figures

343 - Pages

In 2023, the assay kits segment held the largest share of the liquid biopsy market by product & service segment.

Based on product & service, the liquid biopsy market has been segmented into assay kits, instruments, and services. The assay kits segment dominated the liquid biopsy market in 2023. The versatility of assay kits contributes to their market dominance. These kits are adaptable to various biomarkers and analytes, accommodating the diverse needs of liquid biopsy applications, from detecting circulating tumor DNA (ctDNA) to monitoring treatment response and disease progression.

The therapy selection segment held the largest share of the liquid biopsy market by clinical application segment in 2023.

Based on clinical applications, the liquid biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring.  In 2023, the largest share of the liquid biopsy market was held by the therapy selection segment. The growth of therapy selection as the major clinical application segment is fueled by the advantages of liquid biopsy over traditional methods with its minimally invasive, real-time monitoring capabilities across various cancer types, its integration into clinical trials and drug development processes, and its cost-effectiveness in guiding therapy selection.

North America is the largest regional market for liquid biopsy market.

The market for liquid biopsy has been divided into six key geographical regions, namely North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2023, North America held the predominant portion of the liquid biopsy market. The region boasts a well-developed healthcare infrastructure, including advanced diagnostic facilities, specialized oncology centers, and a skilled workforce. This infrastructure supports the integration of liquid biopsy into routine clinical practice, facilitating access for patients across various healthcare settings.

Request Sample Pages:

Liquid Biopsy Market Dynamics:

Drivers:

Rising incidence and prevalence of cancer

Cancer awareness initiatives undertaken by global health organizations

Benefits of liquid biopsy over traditional biopsy procedures

Restraints:

Lower sensitivity of certain liquid biopsy procedures

Opportunities:

Growing significance of companion diagnostics

Growth opportunities in emerging countries

Challenge:

Unclear reimbursement scenario

Key Market Players of Liquid Biopsy Industry:

The major players operating in this market are Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), Guardant Health (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), Sysmex Corporation (Japan), Biocept, In. (US), mdxhealth (US), Personalis, Inc. (US), NeoGenomics Laboratories (US), Epigenomics AG (Germany), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences (US), Bio-Techne (US), MedGenome (US), Mesa Labs, Inc. (US), Laboratory Corporation of America Holdings (US), Freenome Holdings, Inc. (US), Strand (India), LungLife AI, Inc. (US), and Lucence Health Inc. (US).

The break-up of the profile of primary participants in the liquid biopsy market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%

By Designation: C-level - 27%, D-level - 18%, and Others - 55%

By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%

Get 10% Free Customization on this Report:

Recent Developments of Liquid Biopsy Industry:

In February 2024, Myriad Genetics, Inc. (US) entered into a definitive agreement to acquire select assets from Intermountain Health. These included assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory.

In January 2024, Natera, Inc. (US) acquired certain assets relating to non-invasive prenatal and carrier screening business from Invitae (US).

In November 2023, Illumina, Inc. (US) launched its TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2.

In April 2023, QIAGEN (Netherlands) launched the QIAseq Targeted cfDNA Ultra Panels, enabling researchers studying cancer and other diseases to turn cell-free DNA (cfDNA) liquid-biopsy samples into libraries ready for NGS in less than eight hours.

In January 2022, Illumina, Inc. (US) partnered with Boehringer Ingelheim (Germany). This partnership was aimed to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.

Liquid Biopsy Market - Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall liquid biopsy market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Rising incidence and prevalence of cancer, cancer awareness initiatives undertaken by global health organizations, and increased benefits of liquid biopsy over traditional biopsy procedures), opportunities (Growing significance of companion diagnostics and growth opportunities in emerging countries), restraints (Lower sensitivity of certain liquid biopsy procedures), and challenges (Unclear reimbursement scenario) influencing the growth of the liquid biopsy market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the liquid biopsy market.

Market Development: Comprehensive information about lucrative markets – the report analyses the liquid biopsy market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the liquid biopsy market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), and F. Hoffmann-La Roche Ltd (Switzerland).

[marketdevelopment]

Liquid Biopsy Market Size-Share, Growth Factors, Forecast 2023-2030

The Global Liquid Biopsy Market size is expected to grow from USD 1.59 billion in 2022 to USD 7.02 billion by 2030, at a CAGR of 20.4% during the forecast period (2023-2030).

The liquid biopsy market has been witnessing significant growth due to its non-invasive nature and its potential to revolutionize cancer diagnostics and treatment monitoring. Liquid biopsy involves the analysis of biomarkers, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), and exosomes, extracted from bodily fluids like blood and urine. Traditional tissue biopsies are invasive and often provide limited information about tumor heterogeneity, making liquid biopsy an attractive alternative for cancer detection and monitoring.

Factors driving the growth of the liquid biopsy market include advancements in genomic technologies, increasing prevalence of cancer worldwide, rising demand for personalized medicine, and growing awareness about the benefits of early cancer detection. Additionally, the liquid biopsy market is propelled by ongoing research and development activities aimed at enhancing the sensitivity and specificity of liquid biopsy tests, as well as expanding their applications beyond cancer diagnosis to areas such as prenatal testing and organ transplantation monitoring.

Request Sample Copy@:

https://introspectivemarketresearch.com/request/16300

Updated Version 2024 is available our Sample Report May Includes the:

Scope For 2024

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by Worldwide Market Reports 

Moreover, the report includes significant chapters such as Patent Analysis, Regulatory Framework, Technology Roadmap, BCG Matrix, Heat Map Analysis, Price Trend Analysis, and Investment Analysis which help to understand the market direction and movement in the current and upcoming years. 

Leading Key Players Covered Liquid Biopsy Market: -

F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (the US), Guardant Health Inc. (the US), BIOCEPT Inc. (the US), Illumina Inc. (the US), Angle plc (UK), Oncimmune(UK), Lucence health Inc. (US), FreenomeHoldings Inc. (US) and Other Major Players.

Segmentation of Liquid Biopsy Market: -

By Cancer Type         

By Circulating Biomarker     

By End-User   

Market Segment by Regions: -

North America (US, Canada, Mexico)

Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)

Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)

Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)

Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)

South America (Brazil, Argentina, Rest of SA)

If You Have Any Queries Regarding Liquid Biopsy Market, Please Visit:

https://introspectivemarketresearch.com/inquiry/16300

Owning our reports (For More, Buy Our Report) will help you solve the following issues:

1. Uncertainty about the future?

Our research and insights help our clients to foresee upcoming revenue pockets and growth areas. This helps our clients to invest or divest their resources.

2. Understanding market sentiments?

It is imperative to have a fair understanding of market sentiments for a strategy. Our insights furnish you with a hawk-eye view on market sentiment. We keep this observation by engaging with Key Opinion Leaders of a value chain of each industry we track.

3. Understanding the most reliable investment centers?

Our research ranks investment centers of the market by considering their returns, future demands, and profit margins. Our clients can focus on the most prominent investment centers by procuring our market research.

4. Evaluating potential business partners?

Our research and insights help our clients in identifying compatible business partners.

Acquire This Report: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=16300

About us:

Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to helping our clients grow and successfully impact the marketplace. Our team at IMR is ready to help our clients grow their businesses by offering strategies to achieve success and monopoly in their respective fields. We are a global market research company, specializing in the use of big data and advanced analytics to gain a broader picture of market trends. We help our customers to think differently and build a better tomorrow for all of us. As a technology-driven research company, we consider extremely large data sets to uncover deeper insights and provide conclusive consulting. We don't just provide intelligence solutions, we help our clients achieve their goals.

Contact us:

Introspective Market Research

3001 S King Drive,

Chicago, Illinois

60616 USA

Ph no: +1-773-382-1049

Email: sales@introspectivemarketresearch.com

[marketinsight1234]

Liquid Biopsy Market Size-Share, Growth Factors, Forecast 2023-2030

The Global Liquid Biopsy Market size is expected to grow from USD 1.59 billion in 2022 to USD 7.02 billion by 2030, at a CAGR of 20.4% during the forecast period (2023-2030).

The liquid biopsy market has witnessed substantial growth in recent years, driven by advancements in cancer diagnostics and personalized medicine. Unlike traditional biopsy methods, liquid biopsy offers a non-invasive approach to detect and monitor various conditions, particularly cancer, by analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers present in blood or other bodily fluids. The market's growth is propelled by the rising incidence of cancer, increased emphasis on early detection, and the growing adoption of precision medicine.

Request Sample Copy@:

https://introspectivemarketresearch.com/request/16300

Leading Key Players Covered Liquid Biopsy Market: -

F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (the US), Guardant Health Inc. (the US), BIOCEPT Inc. (the US), Illumina Inc. (the US), Angle plc (UK), Oncimmune(UK), Lucence health Inc. (US), FreenomeHoldings Inc. (US) and Other Major Players.

Market Driver:

One key driver fueling the liquid biopsy market is the demand for less invasive and more accessible diagnostic methods. Traditional biopsies are often invasive, requiring surgical procedures that can be uncomfortable and carry potential risks. Liquid biopsies, on the other hand, offer a minimally invasive alternative, reducing patient discomfort and complications. This non-invasiveness enhances patient compliance and enables the monitoring of disease progression over time. As a result, liquid biopsies are increasingly becoming the preferred choice for cancer screening and monitoring, contributing significantly to the market's expansion.

Market Opportunity:

A significant market opportunity lies in the integration of liquid biopsy technologies with artificial intelligence (AI) and machine learning (ML) algorithms. The vast amount of data generated by liquid biopsy tests can be effectively analyzed and interpreted using these advanced technologies. AI and ML can enhance the accuracy of diagnosis, identify subtle biomarker patterns, and provide valuable insights for personalized treatment strategies. Integrating liquid biopsy with AI not only improves the diagnostic capabilities but also opens avenues for predictive and preventive healthcare. This convergence presents a promising opportunity for companies to develop innovative solutions that combine molecular diagnostics with cutting-edge data analytics.

Segmentation of Liquid Biopsy Market: -

By Cancer Type         

By Circulating Biomarker     

By End-User   

If You Have Any Queries Regarding Liquid Biopsy Market, Please Visit:

https://introspectivemarketresearch.com/inquiry/16300

Owning our reports (For More, Buy Our Report) will help you solve the following issues:

1. Uncertainty about the future?

Our research and insights help our clients to foresee upcoming revenue pockets and growth areas. This helps our clients to invest or divest their resources.

2. Understanding market sentiments?

It is imperative to have a fair understanding of market sentiments for a strategy. Our insights furnish you with a hawk-eye view on market sentiment. We keep this observation by engaging with Key Opinion Leaders of a value chain of each industry we track.

3. Understanding the most reliable investment centers?

Our research ranks investment centers of the market by considering their returns, future demands, and profit margins. Our clients can focus on the most prominent investment centers by procuring our market research.

4. Evaluating potential business partners?

Our research and insights help our clients in identifying compatible business partners.

Acquire This Report: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=16300

About us:

Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to helping our clients grow and successfully impact the marketplace. Our team at IMR is ready to help our clients grow their businesses by offering strategies to achieve success and monopoly in their respective fields. We are a global market research company, specializing in the use of big data and advanced analytics to gain a broader picture of market trends. We help our customers to think differently and build a better tomorrow for all of us. As a technology-driven research company, we consider extremely large data sets to uncover deeper insights and provide conclusive consulting. We don't just provide intelligence solutions, we help our clients achieve their goals.

Contact us:

Introspective Market Research

3001 S King Drive,

Chicago, Illinois

60616 USA

Ph no: +1-773-382-1049

Email: sales@introspectivemarketresearch.com

[123567-9qaaq9]

Revolutionizing Cancer Diagnosis: The Evolving Landscape of the Liquid Biopsy Market | BIS Research 

The global liquid biopsy market was estimated to be at $2,508.2 million in 2021, which is expected to grow with a CAGR of 19.83% and reach $19,066.0 million by 2032. The growth in the global liquid biopsy market is expected to be driven by increasing adoption of NGS in various research fields, advancement in NGS, and increase in the adoption of personalized medicine.

Understanding Liquid Biopsy:

Liquid biopsy involves the analysis of biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes, which are released into the bloodstream by cancer cells. This non-invasive method provides valuable insights into the genetic makeup of tumors, allowing for early detection, monitoring of treatment response, and identification of minimal residual disease.

Market Lifecycle Stage

The global liquid biopsy market is still in the nascent phase. Significant increase in the research and development activities pertaining to next-generation sequencing are underway to develop NGS products and services, which are expected to increase due to the rising number of chronic disease burdens such as cancer. Liquid biopsy is a non-invasive medical procedure which holds the ability to detect the presence of molecular cancer biomarkers in biological fluids. The report includes market estimation for tests/services, instruments, kits and consumables used for liquid biopsies of different oncology and non-oncology disorders. Liquid biopsy has a critical role in the precision medicine approach, as it confirms the safe and effective application of targeted therapeutics.

Gain a comprehensive market overview from industry experts and unlock valuable insights to drive your business growth. Download our sample now! @ Liquid Biopsy Market 

Demand – Drivers and Limitations

Following are the demand drivers for the liquid biopsy market:

•    Rising Cancer Prevalence •    Increasing Adoption of Inorganic Growth Strategies in the Market •    Increase in Research Funding from National Cancer Institute

The market is expected to face some limitations too due to the following challenges:

•    Uncertain Reimbursement and Regulatory Policies •    Expected Implementation of Patient Protection and Affordable Care Act in the U.S 

Market Segmentation:

by Offering

by Technology

by Workflow

by Circulating Biomarkers

by Indication

by Clinical Application

by Usage

by End User

by Sample

by Region

Key Players and Competition

The liquid biopsy market is marked by the presence of key players such as Guardant Health, Illumina, Roche Diagnostics, Thermo Fisher Scientific, and Qiagen, among others. These companies are actively engaged in research and development activities to enhance their liquid biopsy technologies, making them more effective in detecting a wide range of cancer types.

Application Across Cancer Types:

Liquid biopsy's versatility is a major factor contributing to its market success. It is not limited to a specific cancer type, making it a valuable tool in the diagnosis and monitoring of various malignancies, including lung, breast, colorectal, prostate, and pancreatic cancers. The ability to analyze genetic mutations specific to each cancer type enhances liquid biopsy's utility across the oncology spectrum.

Challenges and Future Outlook:

While liquid biopsy holds immense promise, it is not without challenges. Standardization of testing methodologies, regulatory approvals, and reimbursement policies are areas that require attention to ensure widespread adoption. Additionally, the constant evolution of cancer genomes poses a challenge in staying ahead with technologies that can effectively detect and analyze these variations.

Looking ahead, the liquid biopsy market is poised for continued growth, with ongoing research and development efforts aimed at improving sensitivity, specificity, and cost-effectiveness. As technology evolves, liquid biopsy is likely to become an integral part of routine cancer care, transforming the landscape of cancer diagnosis and treatment.

Conclusion:

The liquid biopsy market is at the forefront of a revolutionary change in cancer diagnostics, offering a non-invasive and effective alternative to traditional methods. With ongoing advancements in technology, increased awareness, and a growing need for personalized medicine, liquid biopsy is set to play a crucial role in the future of cancer detection and monitoring. As the market continues to expand, collaboration between industry players, healthcare professionals, and regulatory bodies will be essential to overcome challenges and ensure the widespread adoption of this transformative technology.

[researchreport11]

https://www.maximizemarketresearch.com/market-report/breast-cancer-liquid-biopsy-market/12622/

Breast Cancer Liquid Biopsy Market: Global Industry Analysis and Forecast (2023-2029)

Breast Cancer Liquid Biopsy Market is anticipated to reach US$ 1.98 Bn. by 2029 from US$ 0.57 Bn. in 2022 at a CAGR of 19.2% during a forecast period.